Systemic injection of CK2.3, a novel peptide acting downstream of Bone Morphogenetic Protein receptor BMPRIa, leads to increased trabecular bone mass

Bone Morphogenetic Protein 2 (BMP2) regulates bone integrity by driving both osteogenesis and osteoclastogenesis. However, BMP2 as a therapeutic has significant drawbacks. We have designed a novel peptide CK2.3 that blocks the interaction of Casein Kinase 2 (CK2) with Bone Morphogenetic Protein Rece...

Full description

Saved in:
Bibliographic Details
Published in:J Orthop Res
Main Authors: Akkiraju, Hemanth, Bonor, Jeremy, Olli, Kristine, Bowen, Chris, Bragdon, Beth, Coombs, Harold, Donahue, Leah Rae, Duncan, Randall, Nohe, Anja
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304894/
https://ncbi.nlm.nih.gov/pubmed/25331517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jor.22752
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items